ArticleJournal of controlled release : official journal of the Controlled Release Society2026
AI-validated fusion proteins for local inhibition of interleukin-17A.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
IL-17A is a potent immunomodulatory cytokine that is upregulated in many disorders characterized by chronic inflammation, including autoimmune-mediated dry eye observed in patients with Sjögren's Disease. Existing IL-17A inhibiting therapies are delivered systemically and have been associated with increased infection rates in patients. Inhibiting IL-17A signaling locally, only in affected tissues, may provide therapeutic benefits without compromising systemic immune functions. To address this unmet need, we have developed a local IL-17A inhibiting therapy by fusing HAP, a peptide which binds and inhibits IL-17A, with elastin-like polypeptides (ELPs), which are intrinsically disordered thermosensitive protein-polymers that can be engineered to undergo liquid-liquid phase separation to form depots after injection. We show tuning of ELP composition allows us to manipulate the pharmacokinetics, and specifically mean absorption time of our local immunosuppressive depots, demonstrating the potential for extended, local therapy. Furthermore, the fusions retain the binding and inhibitory activity of the HAP peptide, aligning with our in silico predictions using AlphaFold3. Finally, we confirmed that our formulations, which are bacterially derived, do not measurably stimulate the innate or adaptive immune system, which is critical for therapies for autoimmune diseases. Together, these findings establish the utility of our novel peptide-ELP fusions for extended local IL-17A inhibition to address chronic inflammation with fewer off-target effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.